Evaluating NBS in Central Luzon: Progress, Challenges, And Future Directions

by DOH-CHD Central Luzon
 

 
The Department of Health – Central Luzon Center for Health Development (DOH-CLCHD), in partnership with key stakeholders, conducted a comprehensive evaluation of the Newborn Screening (NBS) Program in Central Luzon from February 4 to 7, 2025.
 
The activity aimed to assess the program’s progress, challenges, and future directions while aligning with the Health Sector’s 8-Point Action Agenda. Representatives from the DOH, Newborn Screening Reference Center (NSRC), Center for Human Genetic Services (CHGS), Newborn Screening Center Central Luzon (NSCCL), and other partners participated. Discussions covered NBS performance, achievements beyond the 95% regional and national target, and key concerns such as improving pediatric treatment access and addressing positive screened newborns. The NSRC introduced the NBS Continuity Clinic (NBSCC) Satellite Clinic concept, while the CHGS presented insights on inborn errors of metabolism and dietary management. Plans for establishing an additional NBSCC in 2025 were also discussed to improve follow-up care services.
 
The event also included presentations on the 2023 MNCHN-RH and 2024 NBS performance data, fund utilization, and strategic plans for 2025. Dr. Janet Miclat highlighted future directions using the “SAVES LIVES” (Sustaining momentum, Advance community awareness, Valid data systems, Expanded coverage and access, Support health workers, Link screening to treatment, Integrate services, Value feedback, Enhance collaborations, Strengthen service delivery) framework, emphasizing enhanced awareness, expanded coverage, and strengthened service delivery. Recommendations focused on improving referral pathways, enhancing healthcare provider training, and boosting public awareness initiatives to ensure timely screening and follow-up care. The evaluation concluded with a strengthened commitment among stakeholders to sustain program achievements and improve newborn health outcomes in 2025 and beyond.